

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1138 US		SERIAL NO.: 10/016,651	
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Benjamin OSHLACK, et al.			
				FILING DATE: October 30, 2001		GROUP: 1615	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	AA	3 6 3 4 5 8 4	01/11/72	Poole	424	21	
	AB	3 8 4 5 7 7 0	11/05/74	Theeuwes, et al.	128	260	
	AC	3 8 7 0 7 9 0	03/11/75	Lowey, et al.	424	19	
	AD	3 9 1 6 8 9 9	11/04/75	Theeuwes, et al.	128	260	
	AE	4 3 7 7 5 6 8	03/22/83	Chopra	424	31	
	AF	4 3 8 5 0 7 8	05/24/83	Onda, et al.	427	3	
	AG	4 3 8 9 3 9 3	06/21/83	Schor, et al.	424	19	
	AH	4 4 8 3 8 4 7	11/20/84	Augart	424	22	
	AI	4 5 2 0 1 7 2	05/28/85	Lehmann, et al.	525	369	
	AJ	4 5 4 8 9 9 0	10/22/85	Mueller, et al.	525	123	
		AK	4 5 5 7 9 2 5	12/10/85	Lindahl, et al.	424	19
FOREIGN PATENT DOCUMENTS							
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	AL	0 2 3 5 9 8 6	09/09/87	EPO (A1)	A61K	9/16	
	AM	0 6 6 5 0 1 0	08/02/95	EPO (A1)	A61K	9/26	
	AN	0 2 5 3 1 0 4	01/20/88	EPO (A1)	A61K	9/00	
	AO	0 3 8 8 9 5 4	09/26/90	EPO (A2)	A61K	9/14	
	AP	0 4 1 5 6 9 3	03/06/91	EPO (A1)	A61K	37/02	
	AQ	0 5 3 4 6 2 8	03/31/93	EPO (A1)	A61K	31/485	
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
	AR	Abraham Sunshine et al., "Analgesic Oral Efficacy of Tramadol Hydrochloride in Postoperative Pain," <u>Clin. Pharmacol. Ther.</u> , Vol. 51, June 1992, pages 740-746.					
	AS	E.Beubler, "Medikamentöse Schmerztherapie: Kriterien, Möglichkeiten, Risiken," <u>Therapiewoche Österreich</u> , 7.2 (1992), pages 1-15, English translation.					
	AT	Gourlay, et al., "Influence of a High-Fat Meal On The Absorption of Morphine From Oral Solutions," <u>Clin. Pharmacol. Ther.</u> , Vol. 46, October 1989, pages 463-468					
EXAMINER 				DATE CONSIDERED 10/01/07			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1138US		SERIAL NO.: 10/016,651		
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Benjamin OSHLACK, et al.				
				FILING DATE: October 30, 2001		GROUP: 1615		
U.S. PATENT DOCUMENTS								
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
O/S	BA	4 7 2 8 5 1 3	03/01/88	Ventouras	424	461		
	BB	4 7 0 7 4 1 0	01/10/89	El-Fakahany	514	356		
	BC	4 8 0 6 3 3 7	02/21/89	Snipes, et al.	71	65		
	BD	4 8 2 8 8 3 6	05/09/89	Elger, et al.	424	419		
	BE	4 8 3 4 9 8 4	05/30/89	Goldie, et al.	424	488		
	BF	5 0 0 0 1 1 0	11/26/91	Fawzi, et al.	424	461		
	BG	4 8 4 4 9 0 7	07/04/89	Elger, et al.	424	465		
	BH	5 0 1 0 3 9 7	05/28/91	Wong, et al.	424	473		
	BI	4 9 8 3 7 3 0	01/08/91	Domeshek, et al.	536	69		
	BJ	5 4 5 8 9 2 3	10/10/95	Nakamichi, et al.	424	489		
O/S	BK	5 4 0 0 8 2 6	10/24/95	Merrill, et al.	424	470		
FOREIGN PATENT DOCUMENTS								
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
						YES	NO	
O/S	BL	0 5 3 5 0 4 1	04/07/93	EPO (A1)	A61K	31/485		
	BM	0 5 4 6 6 7 0	06/16/93	EPO (A1)	A61K	31/60		
	BN	0 5 4 8 4 4 8	06/30/93	EPO (A1)	A61K	9/50		
	BO	0 5 8 0 8 0 0	02/02/94	EPO (A1)	A61K	9/14		
	BP	2 1 7 0 3 1 3	02/11/87	Great Britain (A)	A61K	9/14		
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)								
	BQ	Geoffrey K. Gourlay, et al. "The Reproducibility of Bioavailability of Oral Morphine from Solution Under Fed and Fasted Conditions," <u>Journal of Pain and Symptoms Management</u> , Vol. 6., No. 7, October 1991, Pages 431-436						
	BR	Robert F. Kaiko, et al., "Controlled-Release Morphine Bioavailability (MS Contin Tablets) in the Presence and Absence of Food," <u>The Hospice Journal</u> , Vol. 6(4) 1990, pages 17-30.						
O/S	BS	Kaiko, et al., "A Single-Dose Study of The Effect of Food Ingestion and Timing of Dose Administration On The Pharmacokinetic Profile of 30-mg Sustained-Release Morphine Sulfate Tablets," <u>Current Therapeutic Research</u> , Vol. 47, No. 5, May 1990, pages 869-878.						
EXAMINER O/S				DATE CONSIDERED 10/01/07				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1138US		SERIAL NO.: 10/016,651									
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Benjamin OSHLACK, et al.											
				FILING DATE: October 30, 2001		GROUP: 1615									
U.S. PATENT DOCUMENTS															
*EXAMINER INITIAL	CA	DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
	5	5	0	8	0	4	2	04/16/96	Oshlack, et al.	424	468				
	CB	5	5	4	9	9	1	2	08/27/96	Oshlack, et al.	424	468			
	CC	5	6	0	1	8	4	2	02/11/97	Barholomaeus	424	464			
	CD	5	5	2	0	9	3	1	05/28/96	Persson, et al.	424	473			
	CE	5	1	2	2	3	8	4	06/16/92	Paradissis, et al.	424	451			
	CF	4	8	6	1	5	9	8	08/29/89	Oshlack	424	468			
	CG	5	4	1	1	7	4	5	05/02/95	Oshlack, et al.	424	456			
	CH	5	5	0	0	2	2	7	03/19/96	Oshlack, et al.	424	476			
	CI	5	5	8	0	5	7	6	12/03/96	Oshlack, et al.	424	468			
	CJ	5	4	7	2	7	1	2	12/05/95	Oshlack, et al.	424	480			
	CK	5	3	7	8	4	7	4	01/03/95	Morella, et al.	424	469			
	FOREIGN PATENT DOCUMENTS														
			DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO	
		CL	W O	92	0	1	4	4	6	02/06/92	PCT (A1)	A61K	9/50		
CM		W O	92	0	6	6	7	9	04/30/92	PCT (A1)	A61K	9/16			
CN		W O	93	0	4	6	7	5	03/18/93	PCT (A1)	A61K	31/16			
CO		W O	93	1	6	7	5	3	09/30/93	PCT (A1)	A61K	9/16			
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)															
	CP	Yokokawa N., et al., "Relationship between plasma concentration of morphine and analgesic effectiveness," <u>Postgrad Med J</u> , (1991) 67 (Suppl. 2) pages S50-S54.													
	CQ	Physicians Desk Reference 1994, 48 th Edition, pages 1821-1824.													
	CR	D.L. Munday, et al., "Changes in Drug Release Rate 2, Effect of Temperature and Relative Humidity on Polymeric Film Coatings," 5 th Cong. Int. Tech. Pharm., 1989, Vol. 2, pp. 55-60.													
	EXAMINER										DATE CONSIDERED <u>10/01/07</u>				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.															

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1138 US		SERIAL NO.: 10/016,651	
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Benjamin OSHLACK, et al.			
				FILING DATE: October 30, 2001		GROUP: 1615	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	DA	4 9 7 0 6 7 5	11/13/90	Oshlack	424	451	
	DB	5 6 5 6 2 9 5	08/12/97	Oshlack, et al.	424	468	
	DC	5 6 7 0 1 7 2	09/23/97	Buxton, et al.	424	480	
	DD	5 8 7 2 3 6 0	09/30/97	Sackler, et al.	424	490	
	DE	5 5 9 3 6 9 5	01/14/97	Merrill, et al.	424	480	
	DF	5 6 6 7 8 0 5	09/16/97	Merrill, et al.	424	473	
	DG	4 9 9 0 3 4 1	02/05/91	Goldie, et al.	424	484	
	DH	5 2 7 3 7 6 0	12/28/93	Oshlack, et al.	424	480	
	DI	4 8 6 1 5 9 8	08/29/89	Oshlack	424	468	
	DJ	4 8 4 4 9 9 9	07/04/89	Goldie	424	480	
DK	5 2 6 6 3 3 1	11/30/93	Oshlack, et al.	424	468		
FOREIGN PATENT DOCUMENTS							
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	DL	2 1 7 0 1 0 4	07/30/86	United Kingdom (A)	A61K	9/58	
	DM	WO 94 2 2 4 3 1	10/13/94	PCT (A1)	A61K	9/20	
	DN	WO 96 0 0 0 6 6	01/04/96	PCT (A1)	A61K	31/485	
	DO	WO 96 0 1 6 2 9	01/25/96	PCT (A1)	A61K	31/485	
	DP	WO 94 0 5 2 6 2	03/17/94	PCT (A1)	A61K	9/16	
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
	DQ	A Protocol for a clinical study entitled "A Randomized, Double-Blind, Parallel-Group Study comparing the Efficacy and Safety of Kapanol® to MS Contin® in the Management of Patients with Moderate to Severe Cancer Pain" ("the Protocol"). The date of the Protocol is indicated as February 10, 1992 and it bears COD No. 14556. The sponsor of the study is indicated to be Faulding Pharmaceuticals, and Australian company.					
	DR	Certain Patients Diary Cards, Drug Disposition Records, Case Reports Forms and listing which apparently correlates patient randomization number with the treatment of dosing regimen assigned to each patient.					
	DS	Patient consent forms, apparently for four study participants.					
EXAMINER			DATE CONSIDERED				
<small>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>							

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.113BUS		SERIAL NO.: 10/016,651	
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Benjamin OSHLACK, et al.			
				FILING DATE: October 30, 2001		GROUP: 1615	

U.S. PATENT DOCUMENTS													
*EXAMINER INITIAL	DOCUMENT NUMBER	4	8	3	4	9	8	5	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
JS	EA	4	8	3	4	9	8	5	05/30/89	Elger, et al.	424	488	
	EB	5	0	7	1	6	4	6	12/10/91	Malkowska, et al.	424	497	
	EC	5	2	0	2	1	2	8	04/13/93	Morella, et al.	424	469	
	ED	5	1	7	8	8	6	8	01/12/93	Malmqvist, et al.	424	490	
	EE	5	1	3	3	9	7	4	07/28/92	Paradissis, et al.	424	480	
	EF	4	6	0	0	6	4	5	07/15/86	Ghebre-Sellassie, et al.	428	403	
	EG	4	7	0	8	8	7	4	11/24/87	De Haan, et al.	424	470	
	EH	5	0	2	4	8	4	2	06/18/91	Edgren, et al.	424	473	
	EI	5	1	6	9	6	4	5	12/08/92	Shukla, et al.	424	499	
	EJ	5	2	8	3	0	6	5	02/01/94	Doyon, et al.	424	467	
JS	EK	5	3	2	1	0	1	2	06/14/94	Mayer, et al.	514	25	

FOREIGN PATENT DOCUMENTS														
DOCUMENT NUMBER	4	8	3	4	9	8	5	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
												YES	NO	
JS	EL	WO	96	1	4	0	5	8	05/17/96	PCT (A1)	A61K	9/14		
	EM	0	5	3	2	3	4	8	03/17/93	EPO (A2)	A61K	31/35		
	EN	0	6	3	6	3	7	0	02/01/95	EP (B1)	A61K	31/485		
	EO	9	0	4	7	7	3	2	07/12/90	Australia				
	EP	9	3	4	1	6	5	4	02/16/95	Australia				

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)	
EQ	Investigator agreements between the study organizers and certain of the principal investigators.
EXAMINER	<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> </div> <div style="width: 45%;"> DATE CONSIDERED 10/01/07 </div> </div>

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE				ATTY. DOCKET NO.: 200.1138 US		SERIAL NO.: 10/016,651	
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)						APPLICANT(S): Benjamin OSHLACK, et al.			
						FILING DATE: October 30, 2001		GROUP: 1615	
U.S. PATENT DOCUMENTS									
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE			
	FA	4 6 0 9 5 4 2	09/02/86	Panoz, et al.	424	19			
	FB	5 2 0 6 0 3 0	04/27/93	Wheatley, et al.	424	490			
	FC	5 2 1 9 5 7 5	06/15/93	Van Bommel, et al.	424	490			
	FD	5 2 4 8 5 1 6	09/28/93	Wheatley, et al.	427	3			
	FE	5 2 5 8 4 3 6	11/20/93	Wheatley, et al.	524	388			
	FF	5 3 8 4 1 3 0	01/24/95	Kamada	424	461			
	FG	5 6 3 7 3 2 0	06/10/97	Bourke, et al.	424	489			
	FH	5 2 8 6 4 9 3	02/15/94	Oshlack, et al.	424	468			
	FI	5 0 0 7 7 9 0	04/16/91	Shell	424	451			
	FJ	5 3 3 0 7 6 6	07/19/94	Morella, et al.	424	490			
	FK	5 6 8 1 5 8 5	10/28/97	Oshlack, et al.	424	494			
FOREIGN PATENT DOCUMENTS									
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION			
						YES	NO		
	FL	0 2 7 1 1 9 3	06/15/88	EPO (B1)	A61K	31/485			
	FM	0 0 9 7 5 2 3	01/04/84	EPO (A2)	A61K	9/26			
	FN	WO 93 1 0 7 8 5	06/10/93	PCT	A61K	9/22			
	FO	0 3 7 7 5 1 8	07/11/90	EPO (A2)	A61K	9/52			
	FP	WO 94 0 3 1 6 1	02/17/94	PCT	A61K	9/52			
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)									
	FQ	Abstracts from the Twelfth Annual Congress of the Oncology Nursing Society, May 1987, In Clinical Nursing Forum Supplement Vol. 14 (2), p112, 1987.							
	FR	J. Lapin et al., "Cancer Pain Management with a Controlled Release Oral Morphine Preparation," <u>Pain and Symptom Manag.</u> , Vol. 4 (3), pp.146-151, 1989.							
	FS	J. Lapin et al., "Guidelines for Use of Controlled Release Oral Morphine in Cancer Pain Management," <u>Cancer Nursing</u> , Vol. 12 (4), pp. 202-208, (1989).							
EXAMINER 				DATE CONSIDERED 10/01/07					
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.									

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1138 US		SERIAL NO.: 10/016,651	
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Benjamin OSHLACK, et al.			
				FILING DATE: October 30, 2001		GROUP: 1615	

U.S. PATENT DOCUMENTS													
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE							
Q/S	GA 5 4 7 8 5 7 7	12/26/95	Sackler, et al.	424	489								
	GB 6 1 4 3 3 2 2	11/07/00	Sackler, et al.	424	459								
	GC 5 9 5 8 4 5 9	09/28/99	Chasin, et al.	424	490								
	GD 6 1 0 3 2 6 1	08/15/00	Chasin, et al.	424	459								
	GE												
	GF												
	GG												

FOREIGN PATENT DOCUMENTS														
DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION									
					YES	NO								
Q/S	GH 0 3 7 7 5 1 8	11/07/90	EPO (A3)	A61K	9/52									
	GI WO 94 0 3 1 6 0	02/17/94	PCT	A61K	9/32									
	GJ 0 3 7 7 5 1 8	11/07/90	EPO (A2)	A61K	9/52									
	GK 0 3 2 7 2 9 5	08/09/89	EPO (A2)	A61K	9/52									
	GL 0 6 3 6 3 7 0	02/01/95	EPO (A1)	A61K	31/485									
	GM 2 0 8 2 5 7 3	11/10/92	Canada	A61K	047/38									

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)	
GN	R.K. Kaiko, "The Pre-and Postoperative Use of Controlled-Release Morphine (MS Contin Tablets): A Review of the Published Literature," Medical Department, The Purdue Frederick Company, Royal Society of Medical Services, International Congress, Symposium Services, No. 149, pp. 147-160 (1989).
GO	H.F. Slowey et al., "Effect of Premedication with Controlled-Release Oral Morphine on Postoperative Pain," Anaesthesia, 1985, Vol. 40, pp. 438-40.
Q/S	GP MS Contin - Frequency of Daily Dosing, January - November 1990
	GQ
	GR
	GS
GT	

EXAMINER <i>Q/S [Signature]</i>	DATE CONSIDERED 10/01/07
--	---------------------------------





*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1138 US		SERIAL NO.: 10/016,651								
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Benjamin OSHLACK, et al.										
				FILING DATE: October 30, 2001		GROUP: 1615								
U.S. PATENT DOCUMENTS														
*EXAMINER INITIAL		DOCUMENT NUMBER				DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE				
	HA													
	HB													
	HC													
	HD													
	HE													
	HF													
	HG													
	HH													
FOREIGN PATENT DOCUMENTS														
		DOCUMENT NUMBER				DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION				
										YES NO				
	HI	2	1	3	1	3	5	0	01/09/94	Canada (A1)	A61K	031/135		
	HJ	0	1	0	8	2	1	8	05/16/84	EPO (A2)	A61K	9/22		
	HK	0	1	4	7	7	8	0	07/10/85	EPO (A2)	A61K	9/32		
	HL													
	HM													
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)														
	HN	R.K. Portenoy, et al., "A Randomized, Double-Blind, Double-Dummy, Crossover Study Comparing the Pharmacokinetics and Pharmacodynamics of Kapano® Capsules Given Every 24 hours and Every 12 hours with MS Contin® Tablets Given Every 12 Hours in the Management of Patients with Moderate to Severe Chronic Pain" Memorial Hospital IRB Protocol pp. 379-381												
	HO	7 th World Congress on Pain, Abstracts 997-1001, August 26, 1993.												
	HP	Advertisement: Roxanol SR., 1988 Roxane Labs, Inc.												
	HQ	T. Hunt and R. Kaiko, Comparison of the Pharmacokinetic Profiles of Two Oral Controlled-Release Morphine Formulation in Healthy Young Adults, Clin. Thera., Vol. 13, No. 4, pages 482-488, 1991												
	HR	S. Bloomfield, et al. Analgesic Efficacy and Potency of Two Oral Controlled-Release Morphine Preparations Clin. Pharmacol. Ther., Vol. 53, No.4, pages 469-478, 1993												
	HS	Advertisement: MS Contin 1986, 1987 The Purdue Frederick Company.												
EXAMINER							DATE CONSIDERED 10/01/07							
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.														

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE				ATTY. DOCKET NO.: 200.1138 US		SERIAL NO.: 10/016,651								
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)						APPLICANT(S): Benjamin OSHLACK, et al.										
						FILING DATE: October 30, 2001		GROUP: 1615								
U.S. PATENT DOCUMENTS																
*EXAMINER INITIAL	ID	DOCUMENT NUMBER								DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
		1	2	3	4	5	6	7	8					YES	NO	
	IA	4	9	3	5	2	4	6	06/19/90	Ahrens	424	490				
	IB	2	7	3	8	3	0	3	03/13/56	Blythe	167	82				
	IC	5	0	7	6	5	6	0	06/25/91	Makino, et al.	424	494				
	ID	5	1	3	2	1	4	2	07/21/92	Jones, et al.	427	196				
	IE	3	9	1	6	8	8	9	11/04/75	Russell	128	145.8				
	IF	4	0	8	8	8	8	4	05/09/78	Theeuwes, et al.	219	121 LM				
	IG	4	0	6	3	0	6	4	12/13/77	Saunders, et al.	219	121 L				
	IH	4	1	3	2	7	5	3	01/02/79	Blichare, et al.	264	25				
	II	4	4	2	1	7	3	6	12/20/83	Walters	424	19				
	IJ	4	0	9	4	2	3	4	01/16/90	Sharma, et al.	424	440				
	IK	5	0	2	3	0	8	9	06/11/91	Sakamoto, et al.	424	502				
	FOREIGN PATENT DOCUMENTS															
		ID	DOCUMENT NUMBER								DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
			1	2	3	4	5	6	7	8					YES	NO
		IL	WO	93	0	7	8	6	1	04/29/93	PCT (A1)	A61K	9/50			
IM		WO	92	0	2	2	0	9	02/20/92	PCT (A1)	A61K	9/22	(Abstract)			
IN		WO	93	0	7	8	5	9	04/29/93	PCT (A1)	A61K	9/16				
IO		0	2	6	7	7	0	2	05/18/88	EPO (A3)	A61K	9/14				
IP		0	3	6	1	6	8	0	04/04/90	EPO (B1)	A61K	9/46				
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)																
	IQ	Sustained Release Medications, Noyes Data Corp., pages 3,4,10-15, 96-99, 335-337 (1980).														
	IR	Flanders, P., et al. "The Control of Drug Release From Conventional Melt Granulation Matrices," Drug Development and Industrial Pharmacy, Vol. 13, No. 6, pp. 1001-1022 (1987).														
EXAMINER										DATE CONSIDERED						
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.																

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1138 US		SERIAL NO.: 10/016,651	
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Benjamin OSHLACK, et al.			
				FILING DATE: October 30, 2001		GROUP: 1615	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
						YES	NO
	JA	5 0 3 0 4 0 0	07/09/91	Danielsen, et al.	264	101	
	JB	5 1 2 6 1 4 5	06/30/92	Evenstad, et al.	424	465	
	JC	5 1 9 6 2 0 3	03/23/93	Boehm	424	469	
	JD	5 2 9 2 4 6 1	03/08/94	Juch, et al.	264	37	
	JE	5 1 6 7 9 6 4	12/01/92	Muhammed, et al.	424	482	
	JF	4 4 4 3 4 2 8	04/17/84	Oshlack, et al.	424	22	
	JG	5 6 1 4 2 1 8	03/25/97	Olsson, et al.	424	456	
	JH	5 6 2 9 0 1 1	05/13/97	Illum	424	434	
	JI	4 4 6 4 3 7 8	08/07/84	Hussain	424	260	
	JJ	5 5 0 2 0 5 8	03/26/96	Mayer, et al.	514	289	
FOREIGN PATENT DOCUMENTS							
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	JK	0 3 6 1 9 1 0	04/04/90	EPO (A1)	A61K	9/16	
	JL	0 3 7 7 5 1 7	07/11/90	EPO (A2)	A61K	31/52	
	JM	0 4 3 0 2 8 7	06/05/91	EPO (B1)	A61K	9/54	
	JN	0 4 5 2 1 4 5	10/16/91	EPO (A2)	A61K	9/14	
	JO	0 5 5 3 3 9 2	08/04/93	EPO (A1)	A61K	9/50	
	JP	0 5 3 3 2 9 7	03/24/93	EPO (A1)	A61K	9/16	
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
	JQ	McTaggart, Celia M., et al., "The evaluation of formulation and processing conditions of a melt granulation process," <u>International Journal of Pharmaceutics</u> , Vol. 19, pp. 139-148 (1984)					
	JR	Schaefer, T., et al., "Melt granulation in a laboratory scale high shear mixer," <u>Drug Development and Industrial Pharmacy</u> , Vol. 16, No. 8, pp. 1249-1277 (1990)					
	JS	Thomsen, L. Juul, et al., "Prolonged Release Matrix Pellets Prepared by Melt Pelletization I. Process Variables," <u>Drug Development and Industrial Pharmacy</u> , Vol. 19, No. 15, pp. 1867-1887 (1993)					
	JT	Thomsen, L. Juul, "Prolonged Release Matrix Pellets prepared by Melt Pelletization II. Hydrophobic Substances as Melttable Binders Vol. 20, No. 77, pp. 1179-1197 (1994)					
	EXAMINER 			DATE CONSIDERED 10/01/07			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1138 US		SERIAL NO.: 10/016,651								
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Benjamin OSHLACK, et al.										
				FILING DATE: October 30, 2001		GROUP: 1615								
U.S. PATENT DOCUMENTS														
*EXAMINER INITIAL		DOCUMENT NUMBER			DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE					
	KA													
	KB													
	KC													
	KD													
	KE													
	KF													
	KG													
	KH													
	KI													
	KJ													
FOREIGN PATENT DOCUMENTS														
		DOCUMENT NUMBER			DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION					
									YES	NO				
<div style="font-size: 2em;">X</div>	KK	0	6	0	9	9	6	1	08/10/94	EPO (A1)	A61K	31/485		
	KL	0	6	3	6	3	7	0	02/01/95	EPO (A1)	A61K	31/485		
	KM	2	0	5	3	6	6	1	02/11/81	Great Britain (B)	A61K	9/22		
	KN	WO	92	0	8	4	5	9	05/29/92	PCT (A1)	A61K	31/485		
OTHER PRIOR ART (Including Author, Title, Date; Pertinent Pages, Etc.)														
	KO	Thomsen, L. Juul, "Utilizing melt pelletization technique for the preparation of prolonged release products," <u>Pelletization</u> , (material elaborated by assistant prof. Lars Juul Thomsen, Department of Pharmaceutics, Royal Danish School of Pharmacy for the DIE course "Pelletization Technology," November 1992, 106 pages plus 3 appendices)												
	KP	Thomsen, L. Juul, "Prolonged Release Matrix Pellets Prepared by Melt Pelletization. Part IV: Drug Particles Size, and Binder Composition," : <u>Pharmaceutical Technology Europa</u> , pp. 19-24 (October 1994)												
	KQ	Maccarrone C. et al.; "Single Dose Pharmacokinetics of Kapanol™, a New Oral Sustained-Release Morphine Formulation; Clinical Drug Investigation 1994:7 (5) 262-274												
<div style="font-size: 2em;">X</div>	KR	West R. J., et al., "Single dose pharmacokinetics of a new oral sustained release morphine formulation, Kapanol™ capsules," (Abstract 997) International Association for the Study of Pain, 7 th World Congress on Pain, Paris, August 22-27, 1993 (Data on file, Glaxo Australia, F.H. Faulding)												
EXAMINER						DATE CONSIDERED								
						<div style="font-size: 1.5em;">10/01/07</div>								
<small>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>														


FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1138 US		SERIAL NO.: 10/016,651	
LIST OF PRIOR ART CITED BY APPLICANT				APPLICANT(S): Benjamin OSHLACK, et al.			
(Use several sheets if necessary)							
				FILING DATE: October 30, 2001		GROUP: 1615	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	LA						
	LB						
	LC						
	LD						
	LE						
	LF						
	LG						
	LH						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO
	LI	04 0 8 1 0 8 6	04/02/92	Japan	A61K	9/10	X
	LJ						
	LK						
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
	LL	Gourlay GK, et al., "A comparison of Kapanol™ (A new sustained release morphine formulation), MST Continus® and morphine solution in cancer patients: pharmacokinetics aspects." (Abstract 998) International Association for the Study of Pain, 7 th World Congress on Pain Paris, August 22-27, 1993 (Data on file, Glaxo Australia, F.H. Faulding)					
	LM	Cherry DA, et al., "A comparison of Kapanol™ (a new sustained release morphine formulation), MST Continus® and morphine solution in cancer patients: Morphine metabolite profiles and renal function." (Abstract 999) International Association for the Study of Pain, 7 th World Congress on Pain, Paris August 22-27, 1993 (Data on file, Glaxo Australia, F.H. Faulding)					
	LN	Plummer JL, et al., "A comparison of Kapanol™ (a new sustained release morphine formulation) MST Continus® and morphine solution in cancer patients: pharmacodynamic aspects." (Abstract 1000) International Association for the Study of Pain, 7 th World Congress on Pain, Paris, August 22-27, 1993 (Data on file, Glaxo Australia, F.H. Faulding)					
	LO	Toner G, Cramond T, Bishop, et al., "Randomized double blind, phase III crossover study of a new sustained-release oral morphine formulation, Kapanol™ capsules", (Abstract 1001) International Association for the Study on Pain, Paris, August 22-27, 1993 (Data on file, Glaxo Australia, F.H. Faulding)					
	LP	Cherry DA, et al., "Once A Day (i.e. 24 Hourly) Kapanol™, A New Sustained Release Morphine Formulation, in the Treatment of Cancer Pain: Morphine Metabolite Profiles"; European Journal of Cancer; Part A General Topics 1995; 31 (S5) Suppl:S184 Abs 884, European Conference on Clinical Oncology and Cancer Nursing, Paris, 29 Oct-2 Nov 1995.					
				DATE CONSIDERED 10/01/07			
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>							

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1138 US		SERIAL NO.: 10/016,651	
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Benjamin OSHLACK, et al.			
				FILING DATE: October 30, 2001		GROUP: 1615	


U.S. PATENT DOCUMENTS													
*EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
Q/S	MA	5	8	4	3	4	8	0	12/01/98	Miller, et al.	424	484	
	MB	5	8	4	9	2	4	0	12/15/98	Miller, et al.	264	463	
	MC	5	8	7	9	7	0	5	03/09/99	Heafield, et al.	424	464	
	MD	5	8	9	1	4	7	1	04/06/99	Miller, et al.	424	468	
	ME	5	9	6	5	1	6	3	10/12/99	Miller, et al.	424	468	
	MF	5	9	6	8	5	5	1	10/19/99	Oshlack, et al.	424	456	
	MG	5	1	3	3	9	7	4	07/28/92	Paradissis, et al.	424	480	
	MH	5	2	6	6	3	3	1	11/30/93	Oshlack, et al.	424	468	
	MI	5	6	5	6	2	9	5	08/12/97	Oshlack, et al.	424	468	
	MJ	5	6	7	0	1	7	2	09/23/97	Buxton, et al.	424	495	
Q/S	MK	5	6	7	2	3	6	0	09/30/97	Sackler, et al.	424	490	
	ML	5	6	8	1	5	8	5	10/28/97	Oshlack, et al.	424	494	
	MM	4	8	4	4	9	0	9	07/04/89	Goldie, et al.	424	480	

FOREIGN PATENT DOCUMENTS														
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
	MN													

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)	
Q/S	MO Gourlay, et al., "Once A Day (i.e. 24 Hourly) Kapanol™, A New Sustained Release Morphine Formulation, In The Treatment of Cancer Pain: Pharmacokinetic Aspects", European Journal of Cancer; Part A General Topics 1995:31 (S5) Suppl: S187 Abs 897, European Conference on Clinical Oncology and Cancer Nursing, Paris, 29 Oct-2 Nov 1995
	MP Broomhead, et al. "Kadian™/Kapanol™-A Once Daily Morphine Formulation" European Journal of Cancer; Part A General Topics 1995:31 (S5) Suppl: S182 Abs 873, European Conference on Clinical Oncology and Cancer Nursing, Paris, 29 Oct-2 Nov 1995
	MQ Gourlay et al., Proceedings of the 7 th World Congress on Pain; A comparison of Kapanol (a New Sustained-Release Morphine Formulation), MST Continus, and Morphine Solution in Cancer Patients: Pharmacokinetic Aspects of Morphine and Morphine Metabolites Progress in Pain Research and Management Volume 2 pp 631-643
	MR Kaiko R.F., "Clinical Protocol and Role of Controlled Release Morphine in the Surgical Patient," Anesthesiology and Pain Management 1991 pp 193-212
Q/S	MS MS Contin - Frequency of Daily Dosing (NDTI) - June, 1991 - May, 1992

EXAMINER 	DATE CONSIDERED 10/01/07
---	-----------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1138 US		SERIAL NO.: 10/016,651								
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Benjamin OSHLACK, et al.										
				FILING DATE: October 30, 2001		GROUP: 1615								
U.S. PATENT DOCUMENTS														
*EXAMINE R INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	NA													
	NB													
	NC													
	ND													
FOREIGN PATENT DOCUMENTS														
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
9/8	NE	0	5	3	2	3	4	8	03/17/93	EP (A3)	C07C	291/04		
	NF	0	5	3	2	3	4	8	03/17/93	EP (B1)	C07C	291/04		
	NG	0	5	3	4	6	2	8	03/31/93	EP (B1)	A61K	31/485		
	NH	0	2	5	3	1	0	4	01/20/88	EPO (B1)	A61K	9/00		
	NI	0	2	3	5	9	8	6	09/09/87	EPO (B1)	A61K	9/16		
	NJ	0	2	3	5	9	8	6	09/09/87	EP (B2)	A61K	9/16		
	NK	0	3	7	7	5	1	8	07/11/90	EPO (A3)	A61K	9/52		
	NL	0	3	8	8	9	5	4	09/26/90	EPO (A3)	A61K	9/14		
9/8	NM	0	3	8	8	9	5	4	09/26/90	EPO (B1)	A61K	9/14		
	NN	0	0	9	7	5	2	3	01/04/84	EPO (B1)	A61K	9/26		
NPHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)														
	NQ													
EXAMINER 										DATE CONSIDERED 10/01/07				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.														

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1138 US		SERIAL NO.: 10/016,651									
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Benjamin OSHLACK, et al.											
				FILING DATE: October 30, 2001		GROUP: 1615									
U.S. PATENT DOCUMENTS															
*EXAMINER INITIAL:	DOCUMENT NUMBER	DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
		AA	5	6	6	6	1	6						1	
	AA	5	6	6	6	1	6	1	02/02/1999	Childers, et al.	424	465			
	AB	6	4	9	1	9	4	5	12/10/2002	Childers, et al.	424	465			
	AC														
	AD														
	AE														
	AF														
	AG														
	AH														
	AI														
	AJ														
	AK														
FOREIGN PATENT DOCUMENTS															
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
		AL	AM	AN	AO	AP	AQ	YES					NO		
	AL														
	AM														
	AN														
	AO														
	AP														
	AQ														
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)															
	AR														
	AS														
	AT														
EXAMINER 										DATE CONSIDERED 10/01/07					
<small>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>															

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1138CON		SERIAL NO.: 10/660,349							
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Benjamin OSHALCK et al.									
				FILING DATE: September 11, 2003		GROUP: 1615							
U.S. PATENT DOCUMENTS													
*EXAMINER INITIAL	AA	DOCUMENT NUMBER						DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	AA												
	AB												
	AC												
	AD												
	AE												
	AF												
	AG												
FOREIGN PATENT DOCUMENTS													
		DOCUMENT NUMBER						DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
												YES NO	
/HS/	AH	9	7	3	3	5	6	6	09/18/1997	WO(A2)	A61K	9/20	
	AI												
	AJ												
	AK												
	AL												
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)													
/HS/	AM	Santus G., and Baker. R.W., "Osmotic drug delivery: a review of the patent literature", J Controlled Release (1995) Vol 35 pp 1-21											
	AN												
	AO												
	AP												
	AQ												
	AR												
	AS												
EXAMINER /Humera Sheikh/									DATE CONSIDERED 10/01/2007				
<small>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>													